Lupus drug Benlysta effective for SLE patients
Lupus Research Institute Highly Encouraged by Benlysta Trial Results — First Phase 3 Lupus Drug Trial in Decades to Show Effectiveness. – Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA (belimumab, formerly LymphoStat-B?) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).